CN108125940A - Valeric acid is being prepared for preventing and/or treat the purposes in the drug of neoplasm radiotheraphy secondary reaction - Google Patents
Valeric acid is being prepared for preventing and/or treat the purposes in the drug of neoplasm radiotheraphy secondary reaction Download PDFInfo
- Publication number
- CN108125940A CN108125940A CN201711456216.9A CN201711456216A CN108125940A CN 108125940 A CN108125940 A CN 108125940A CN 201711456216 A CN201711456216 A CN 201711456216A CN 108125940 A CN108125940 A CN 108125940A
- Authority
- CN
- China
- Prior art keywords
- neoplasm
- valeric acid
- secondary reaction
- tumor
- preventing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention belongs to pharmaceutical technology field, it is related to valeric acid preparing for preventing and/or treating the purposes in the drug of neoplasm radiotheraphy secondary reaction.It is found by studying, valeric acid can significantly improve mouse damage of intestines as caused by gamma-rays abdomen local irradiation, the survival rate for showing as experiment mice dramatically increases, weight is gone up, intestinal inflammatory level significantly reduces, and experiment mice does not show abnormal response, shows that valeric acid can be effective for preventing and/or treating neoplasm radiotheraphy secondary reaction, and itself toxic side effect is relatively low.
Description
Technical field
The invention belongs to pharmaceutical technology field, it is related to valeric acid preparing for preventing and/or treating neoplasm radiotheraphy secondary reaction
Drug in purposes more particularly to valeric acid preparing for preventing and/or treat the drug of basin abdominal tumor radiotheraphy secondary reaction
In purposes.
Background technology
Epidemiological study shows that cancer has become global one of illness rate and the highest disease of the death rate.Cancer in 2017
Disease report display：Daily about 10,000 people are diagnosed as cancer, and average minute clock just has 7 people to make a definite diagnosis.World's new cases about 1409
Ten thousand, Chinese new cases account for the 1/4 of the world.
Basin abdominal tumor includes digestive system tumor (such as：Gastric cancer, liver cancer, cancer of pancreas, colon and rectum carcinoma etc.), uropoiesis
System tumor is (such as：Kidney, carcinoma of urinary bladder etc.), andrology's tumour (such as：Prostate cancer, carcinoma of testis etc.) and gynecological tumor is (such as：Uterine neck
Cancer, oophoroma etc.).In newly-increased cancer patient, basin abdominal tumor is suffered from more than 1/3rd；And in four dead people
Just there is a people to die of cancer.The general volume of basin abdominal tumor is larger, and is easily transferred to other organs of abdominal cavity or lymphatic system, therefore
It is larger to treat difficulty.
Radiotherapy is a kind of conventional means of oncotherapy, and most basin abdominal tumor patients are in its preoperative, art or art
After need to receive radiotherapy as its main or auxiliary treatment means.But small intestine is as radiosensitive organ, in radiotherapy
It is highly susceptible to damage.Most patients are after abdominopelvic cavity radiotherapy is received, it may appear that typical gastrointestinal syndrome, such as vomiting,
Diarrhea, enteritis and nutrient absorption are bad etc., seriously affect the rehabilitation course after Patients Treated by Radiotherapy, even result in death.
At present, the drug of alleviation radiotheraphy secondary reaction clinically applied only has Amifostine (Amifostine).Radiotherapy it
Before, it is tumor patient intravenous drip Amifostine according to body surface area, can significantly alleviates side reaction caused by radiotherapy.But ammonia
Phosphorus spit of fland can quickly be removed in blood plasma, and it is only 8 minutes to exclude half-life period.After medication 6 minutes, only less than 10% ammonia
Phosphorus spit of fland is remaining in blood plasma.In addition, intravenous Amifostine is also possible to induce a series of side reactions, mainly low blood pressure, account for about 57%,
Other reactions include having metallic taste in Nausea and vomiting, dizziness, fever, mild drowsiness, mouth, occasionally there is allergy.
To sum up, due to duration of efficacy is short after Amifostine medication and itself medication after there are side reactions, limit it
Extensive use clinically.In consideration of it, there is an urgent need for exploitation one kind can effectively prevent and/or treat neoplasm radiotheraphy secondary reaction and oneself
The relatively low drug of body toxic side effect.
Invention content
Problems to be solved by the invention
In order to probe into drug for the relationship between the control effect of neoplasm radiotheraphy secondary reaction and its own toxic side effect, into
And neoplasm radiotheraphy secondary reaction can effectively be prevented and/or treat and the relatively low drug of itself toxic side effect, the present invention carry by developing
Valeric acid has been supplied to prepare the medicine for preventing and/or treating neoplasm radiotheraphy secondary reaction (particularly basin abdominal tumor radiotheraphy secondary reaction)
Purposes in object.
The solution to the problem
On the one hand, the present invention provides valeric acids to prepare for preventing and/or treat in the drug of neoplasm radiotheraphy secondary reaction
Purposes.
Further, the tumour is basin abdominal tumor.
Further, the neoplasm radiotheraphy secondary reaction including but not limited to vomiting, diarrhea, enteritis, nutrient absorption is bad
Deng.
Further, the basin abdominal tumor includes but is not limited to digestive system tumor, Patients with Urinary System Tumors, andrology
Tumour, gynecological tumor etc..
Still further, the digestive system tumor includes but is not limited to gastric cancer, liver cancer, cancer of pancreas, colon cancer, rectum
Cancer etc.；The Patients with Urinary System Tumors includes but is not limited to kidney, carcinoma of urinary bladder etc.；Before andrology's tumour includes but is not limited to
Row gland cancer, carcinoma of testis etc.；The gynecological tumor includes but is not limited to cervical carcinoma, oophoroma etc..
On the other hand, the present invention provides a kind of for preventing and/or treating the pharmaceutical composition of neoplasm radiotheraphy secondary reaction,
It includes valeric acid and one or more pharmaceutically acceptable carriers or it includes valeric acid and one or more tumor radiotherapy pairs
React protective agents.
Further, the tumour is basin abdominal tumor.
Further, the neoplasm radiotheraphy secondary reaction including but not limited to vomiting, diarrhea, enteritis, nutrient absorption is bad
Deng.
Further, the basin abdominal tumor includes but is not limited to digestive system tumor, Patients with Urinary System Tumors, andrology
Tumour, gynecological tumor etc..
Still further, the digestive system tumor includes but is not limited to gastric cancer, liver cancer, cancer of pancreas, colon cancer, rectum
Cancer etc.；The Patients with Urinary System Tumors includes but is not limited to kidney, carcinoma of urinary bladder etc.；Before andrology's tumour includes but is not limited to
Row gland cancer, carcinoma of testis etc.；The gynecological tumor includes but is not limited to cervical carcinoma, oophoroma etc..
Further, the pharmaceutically acceptable carrier includes but is not limited to solvent, solubilizer, cosolvent, emulsification
Agent, rectifys olfactory agent, colorant, adhesive, disintegrant, filler, lubricant, wetting agent, osmotic pressure regulator, pH tune at corrigent
Save agent, stabilizer, surfactant, preservative etc..
Further, the neoplasm radiotheraphy secondary reaction protective agents include but is not limited to Amifostine, Tiopronin
(Tiopronin), Aprepitant (Aprepitant), Tropisetron (Tropisetron), Ondansetron (Ondansetron),
Granisetron (Granisetron), palonosetron (Palonosetron) etc..
Another aspect, the present invention provides a kind of for preventing and/or treating the pharmaceutical preparation of neoplasm radiotheraphy secondary reaction,
Valeric acid comprising therapeutically effective amount and one or more pharmaceutically acceptable carriers.
Further, the tumour is basin abdominal tumor.
Further, the neoplasm radiotheraphy secondary reaction including but not limited to vomiting, diarrhea, enteritis, nutrient absorption is bad
Deng.
Further, the basin abdominal tumor includes but is not limited to digestive system tumor, Patients with Urinary System Tumors, andrology
Tumour, gynecological tumor etc..
Still further, the digestive system tumor includes but is not limited to gastric cancer, liver cancer, cancer of pancreas, colon cancer, rectum
Cancer etc.；The Patients with Urinary System Tumors includes but is not limited to kidney, carcinoma of urinary bladder etc.；Before andrology's tumour includes but is not limited to
Row gland cancer, carcinoma of testis etc.；The gynecological tumor includes but is not limited to cervical carcinoma, oophoroma etc..
Further, the pharmaceutically acceptable carrier includes but is not limited to solvent, solubilizer, cosolvent, emulsification
Agent, rectifys olfactory agent, colorant, adhesive, disintegrant, filler, lubricant, wetting agent, osmotic pressure regulator, pH tune at corrigent
Save agent, stabilizer, surfactant, preservative etc..
Further, the pharmaceutical preparation is solid pharmaceutical preparation, semisolid preparation or liquid preparation.
Further, the solid pharmaceutical preparation includes but is not limited to tablet, capsule, granule, pill etc.；Described half
Solid pharmaceutical preparation includes but is not limited to gelling agent, suppository, paste etc.；The liquid preparation include but is not limited to emulsion, mixture,
Suspension, solution etc..
The effect of invention
The present invention passes through the study found that valeric acid can significantly improve mouse intestines damage as caused by gamma-rays abdomen local irradiation
Wound, the survival rate for showing as experiment mice dramatically increase, and weight is gone up, and intestinal inflammatory level significantly reduces, and test small
Mouse does not show abnormal response, shows that valeric acid can be effective for preventing and/or treating neoplasm radiotheraphy secondary reaction, and itself poison is secondary
It acts on relatively low.
Description of the drawings
Fig. 1 is survival rate situation of the mouse after gamma-rays abdomen local irradiation.
Fig. 2 is body weights of the mouse after gamma-rays abdomen local irradiation.
Fig. 3 is enteron aisle goblet cell quantity situation of change of the mouse after gamma-rays abdomen local irradiation.
Fig. 4 is colon lengths situation of change of the mouse after gamma-rays abdomen local irradiation, wherein (a) shines for mouse Colon
Piece, (b) count block diagram for mouse Colon length.
Fig. 5 is mouse through Amifostine and valeric acid treated survival rate situation.
Specific embodiment
First, the present invention provides valeric acids to prepare for preventing and/or treat in the drug of neoplasm radiotheraphy secondary reaction
Purposes.
In the context of the present invention, term " neoplasm radiotheraphy secondary reaction " refers to tumor patient through one caused by radiotherapy
Serial malaise symptoms are mainly shown as Nausea and vomiting, apocleisis, malnutrition, hemogram abnormity, inflammation, hypoimmunity, skin
Itch, tired burnout etc..
In a preferred embodiment, above-mentioned neoplasm radiotheraphy secondary reaction is led to carry out radiotherapy for basin abdominal tumor
The side reaction of cause, it is mainly bad etc. including vomiting, diarrhea, enteritis, nutrient absorption, wherein：When vomiting and diarrhea are tumor radiotherapies
Common side reaction causes gastrointestinal dysfunction due to radiotherapy mostly；Radiation enteritis is basin abdominal tumor through caused by radiation
Intestinal tract complication and tumor radiotherapy when common side reaction；In addition, tumor patient often will appear saliva in Patients During Radiotherapy
The phenomenon that liquid is reduced, had sore throat, dysphagia directly affects the diet situation of patient, so that there is different degrees of nutrition
It is bad.
In the context of the present invention, term " basin abdominal tumor " refers to swollen on the organ being located in pelvic cavity or abdominal cavity
Knurl relates generally to digestion, uropoiesis and reproduction three digest journals, wherein：Digestive system tumor mainly include gastric cancer, liver cancer, cancer of pancreas,
Colon and rectum carcinoma etc.；Patients with Urinary System Tumors mainly includes kidney, carcinoma of urinary bladder etc.；Genital system mainly swells including andrology
Cervical carcinoma, oophoroma in prostate cancer, carcinoma of testis in knurl etc. and gynecological tumor etc..
Secondly, it is above-mentioned the present invention provides a kind of for preventing and/or treating the pharmaceutical composition of neoplasm radiotheraphy secondary reaction
Pharmaceutical composition includes valeric acid and one or more pharmaceutically acceptable carriers or includes valeric acid and one or more tumours
Radiotheraphy secondary reaction protective agents.
In the context of the present invention, term " pharmaceutically acceptable carrier " refers to be suitable for thin with human body or animal body
Born of the same parents, tissue or organ are compatible, and will not induce the adjunct ingredient of the toxic side effects such as toxicity, irritation, allergy." pharmacy
Upper acceptable carrier " be it is known in the art, mainly including solvent, solubilizer, cosolvent, emulsifier, corrigent, rectify and smell
Agent, colorant, adhesive, disintegrant, filler, lubricant, wetting agent, osmotic pressure regulator, pH adjusting agent, stabilizer, table
Face activating agent, preservative etc..
In the context of the present invention, term " neoplasm radiotheraphy secondary reaction protective agents " refer to can be used in prevention and/or
Treat the drug of side reaction of the tumor patient through caused by radiation." neoplasm radiotheraphy secondary reaction protective agents " are known in the art
, mainly including Amifostine, Tiopronin, Aprepitant, Tropisetron, Ondansetron, Granisetron, palonosetron etc..
In a preferred embodiment, aforementioned pharmaceutical compositions do not include other active components, the i.e. pharmaceutical composition
Object is made of valeric acid and one or more pharmaceutically acceptable carriers.
Finally, the present invention provides a kind of for preventing and/or treating the pharmaceutical preparation of neoplasm radiotheraphy secondary reaction, above-mentioned medicine
Object preparation includes the valeric acid of therapeutically effective amount and one or more pharmaceutically acceptable carriers.
In the context of the present invention, term " therapeutically effective amount " refers to pure form or itself and other substances
Dosage when form of mixtures is existing, biologically active compound can realize any one following effect：(1) prevent
Or treatment specified disease, illness or obstacle；(2) mitigation, improvement or the one or more diseases for eliminating specified disease, illness or obstacle
Shape；Or the breaking-out of one or more symptoms of specified disease, illness or obstacle is prevented or delayed in (3).
In a preferred embodiment, said medicine preparation is the valeric acid comprising therapeutically effective amount and one or more
Solid pharmaceutical preparation, semisolid preparation or the liquid preparation of pharmaceutically acceptable carrier, wherein：Applicable solid dosage form is main
Including tablet, capsule, granule, pill etc.；Applicable semisolid preparation form mainly includes gelling agent, suppository, paste etc.；
Applicable liquid forms mainly include emulsion, mixture, suspension, solution etc..
Again time, the present invention provides a kind of valeric acid, the pharmaceutical composition comprising valeric acid or the pharmaceutical preparation comprising valeric acid,
For preventing and/or treating neoplasm radiotheraphy secondary reaction, wherein：Being used for for the preferred present invention of the pharmaceutical composition for including valeric acid is pre-
Pharmaceutical composition that is anti-and/or treating neoplasm radiotheraphy secondary reaction, is somebody's turn to do being used in advance for the preferred present invention of the pharmaceutical preparation comprising valeric acid
Anti- and/or treatment neoplasm radiotheraphy secondary reaction pharmaceutical preparation.
Finally, the present invention provides a kind of method for preventing and/or treating neoplasm radiotheraphy secondary reaction, including subject to
Standby tumour (the particularly basin abdominal tumor) patient for receiving, receiving or receiving radiotherapy applies therapeutically effective amount
The step of valeric acid, the pharmaceutical composition comprising valeric acid or pharmaceutical preparation comprising valeric acid, wherein：This includes the pharmaceutical composition of valeric acid
The pharmaceutical composition for being used to prevent and/or treat neoplasm radiotheraphy secondary reaction of the preferred present invention of object should include the drug system of valeric acid
The preferred present invention of agent for preventing and/or treating the pharmaceutical preparation of neoplasm radiotheraphy secondary reaction, and the therapeutically effective amount for 75~
3750mg valeric acids/kg body weight/days, preferably 150mg valeric acids/kg body weight/days.
Carry out the technical solution during the present invention is further explained below with reference to specific embodiment.Under it should be understood that
Row embodiment is only used for the explanation and illustration present invention, and the protection domain being not intended to restrict the invention.Unless otherwise indicated, under
Instrument, material and reagent for being used in row embodiment etc. can be obtained by routine business means.
Embodiment one：Survival rate and weight detection of the mouse after gamma-rays abdomen local irradiation.
1st, experimental animal：
C57BL/6J mouse, 6-8 week old, weight about 20g, male are randomly divided into two groups：Control group and valeric acid administration group,
Every group 30.
2nd, model foundation：
After using 0.3% chloral hydrate anesthesia experiment mice (anaesthesia dosage 1ml/g), use
40Exactor to mouse full abdomen carry out the local irradiation of gamma-rays abdomen (40Exactor carries local irradiation
Mold, all exposures of entire abdomen), absorbed dose of radiation 15Gy, dosage rate 1Gy/min.
3rd, administering mode：
Valeric acid administration group：Start to be administered for 24 hours after irradiation, administering mode：Valeric acid liquid gastric infusion, 2 points of every afternoon are given
Medicine 1 time, successive administration 21 days；Dosage：200 μ l//times；Valeric acid liquid (aqueous solution) concentration：15mg/ml.
Control group：Start to be administered for 24 hours after irradiation, administering mode：Pure water gastric infusion, 2 points of every afternoon are administered once,
Successive administration 21 days；Dosage：200 μ l//times.
4th, observation index：
The death toll of each group mouse, continuous monitoring 21 days, with Kaplan-Meier survival rates point are observed and recorded in time
Analysis method carries out statistical procedures, acquires the survival rate of each group experiment mice, the results are shown in Figure 1.In addition, it observes and remembers in time
The whose body weight of each group mouse is recorded, continuous monitoring 21 days acquires the average weight of each group experiment mice, the results are shown in Figure 2.
5th, result and conclusion：
As a result：As shown in Figure 1, mouse is after gamma-rays abdomen local irradiation, with 3mg valeric acids/pcs/day dosage connect
Continuous gavage 21 days can significantly improve the survival rate (P of experiment mice<0.05)；As shown in Figure 2, mouse is through gamma-rays abdomen office
After portion's irradiation, with 3mg valeric acids/pcs/day dosage continuous gavage 21 days, can significantly alleviate mouse body as caused by radiation
Decline (P again<0.05).
Conclusion：Valeric acid can significantly improve survival rate and weight of the experiment mice after gamma-rays abdomen local irradiation, right
The side reaction as caused by ionising radiation has significant improvement result.
Embodiment two：Enteron aisle goblet cell detection of the mouse after gamma-rays abdomen local irradiation.
1st, experimental animal：
C57BL/6J mouse, 6-8 week old, weight about 20g, male are randomly divided into three groups：Blank group, simple irradiation group and
Valeric acid administration group, every group 30.
2nd, model foundation：
After using 0.3% chloral hydrate anesthesia experiment mice (anaesthesia dosage 1ml/g), use
40Exactor to mouse full abdomen carry out the local irradiation of gamma-rays abdomen (40Exactor carries local photograph
Penetrate mold, all exposures of entire abdomen), absorbed dose of radiation 12Gy, dosage rate 1Gy/min.
3rd, administering mode：
Valeric acid administration group：Start to be administered for 24 hours after irradiation, administering mode：Valeric acid liquid gastric infusion, 2 points of every afternoon are given
Medicine 1 time, successive administration 21 days；Dosage：200 μ l//times；Valeric acid liquid (aqueous solution) concentration：15mg/ml.
Simple irradiation group：Start to be administered for 24 hours after irradiation, administering mode：Pure water gastric infusion, 2 points of administrations 1 every afternoon
It is secondary, successive administration 21 days；Dosage：200 μ l//times.
Blank group：Do not receive irradiation, administering mode：Pure water gastric infusion, 2 points of every afternoon are administered once, successive administration
21 days；Dosage：200 μ l//times.
4th, observation index：
Administration puts to death mouse after 21 days, the small intestine of each group mouse is taken to be placed in embedded box, in Ka Nuoshi fixers
It is fixed in (Carnoy's fixative) to stay overnight, dehydration, embedding, slice, using periodic acid-Xue Fu (AB-PAS) staining reagent
Box detects the quantity of each group mouse intestinal goblet cell.
5th, result and conclusion：
As a result：From the figure 3, it may be seen that compared with naive mice, after gamma-rays abdomen local irradiation, simple irradiation group mouse
The quantity of goblet cell is remarkably decreased in small intestine.However, compared with simple irradiation group mouse, with 3mg valeric acids/pcs/day
Dosage continuous gavage 21 days can dramatically increase the quantity of goblet cell in valeric acid administration group mouse small intestine tissue, so as to
Improve the integrality and function of small intestine.
Conclusion：Valeric acid can reduce the toxic side effect as caused by gamma-rays abdomen local irradiation.
Embodiment three：Colon lengths detection of the mouse after gamma-rays abdomen local irradiation.
1st, experimental animal：
C57BL/6J mouse, 6-8 week old, weight about 20g, male are randomly divided into three groups：Blank group, simple irradiation group and
Valeric acid administration group, every group 30.
2nd, model foundation：
After using 0.3% chloral hydrate anesthesia experiment mice (anaesthesia dosage 1ml/g), use
40Exactor to mouse full abdomen carry out the local irradiation of gamma-rays abdomen (40Exactor carries local irradiation
Mold, all exposures of entire abdomen), absorbed dose of radiation 12Gy, dosage rate 1Gy/min.
3rd, administering mode：
Valeric acid administration group：Start to be administered for 24 hours after irradiation, administering mode：Valeric acid liquid gastric infusion, 2 points of every afternoon are given
Medicine 1 time, successive administration 21 days；Dosage：200 μ l//times；Valeric acid liquid (aqueous solution) concentration：15mg/ml.
Simple irradiation group：Start to be administered for 24 hours after irradiation, administering mode：Pure water gastric infusion, 2 points of administrations 1 every afternoon
It is secondary, successive administration 21 days；Dosage：200 μ l//times.
Blank group：Do not receive irradiation, administering mode：Pure water gastric infusion, 2 points of every afternoon are administered once, successive administration
21 days；Dosage：200 μ l//times.
4th, observation index：
Administration puts to death mouse after 21 days, takes the colon of each group mouse, takes pictures and measure the colon lengths of every mouse.
5th, result and conclusion：
As a result：As shown in Figure 4, compared with naive mice, after gamma-rays abdomen local irradiation, simple irradiation group mouse
Colon lengths be obviously shortened.However, compared with simple irradiation group mouse, with 3mg valeric acids/pcs/day dosage continuously fill
Stomach 21 days can dramatically increase the colon lengths of valeric acid administration group mouse.
Conclusion：Valeric acid can reduce the intestinal inflammatory level as caused by gamma-rays abdomen local irradiation, mitigate the poison of irradiation
Side effect.
Example IV：The toxicity of neoplasm radiotheraphy secondary reaction protective agents compares.
1st, experimental animal：
C57BL/6J mouse, 6-8 week old, weight about 20g, male are randomly divided into two groups：Amifostine administration group and valeric acid are given
Medicine group, every group 20.
2nd, model foundation：
C57BL/6J mouse give Amifostine processing or valeric acid processing respectively without irradiation.
3rd, administering mode：
Amifostine administration group：It is administered once, administering mode：Intraperitoneal injection, 2 points of administrations every afternoon；Dosage：200μ
L/ is only；Amifostine liquid (normal saline solution) concentration：80mg/ml.
Valeric acid administration group：It is administered once, administering mode：Valeric acid liquid gastric infusion, 2 points of administrations every afternoon；To medicament
Amount：200 μ l/ are only；Valeric acid liquid (aqueous solution) concentration：80mg/ml.
4th, observation index：
Amifostine administration group and the death toll of valeric acid administration group mouse are observed and recorded in time, continuous monitoring 21 days is used
Kaplan-Meier survival Analysis method carries out statistical procedures, acquires the survival rate of two groups of experiment mices, result such as Fig. 5 institutes
Show.
5th, result and conclusion：
As a result：As shown in Figure 5, with 16mg Amifostines/only dosage be injected intraperitoneally 1 time after, the life of mouse after 21 days
The rate of depositing is only 50% or so；And do not occur death (P with mouse after the dosage gavage 1 time, 21 days of 16mg valeric acids/only<
0.05)。
Conclusion：Compared with Amifostine, valeric acid does not have apparent toxic side effect, is more suitable for preventing and/or treating tumour
Radiotheraphy secondary reaction.
Claims (11)
1. valeric acid is being prepared for preventing and/or treat the purposes in the drug of neoplasm radiotheraphy secondary reaction.
2. purposes according to claim 1, it is characterised in that：The tumour is basin abdominal tumor.
3. purposes according to claim 1 or 2, it is characterised in that：The neoplasm radiotheraphy secondary reaction include vomiting, diarrhea,
Enteritis and/or nutrient absorption are bad.
4. purposes according to claim 2, it is characterised in that：The basin abdominal tumor includes digestive system tumor, uropoiesis
System tumor, andrology's tumour and/or gynecological tumor.
5. purposes according to claim 4, it is characterised in that：The digestive system tumor includes gastric cancer, liver cancer, pancreas
Cancer, colon cancer and/or the carcinoma of the rectum；The Patients with Urinary System Tumors includes kidney and/or carcinoma of urinary bladder；Andrology's tumour includes forefront
Gland cancer and/or carcinoma of testis；The gynecological tumor includes cervical carcinoma and/or oophoroma.
6. a kind of for preventing and/or treating the pharmaceutical composition of neoplasm radiotheraphy secondary reaction, it includes valeric acids and one or more
Pharmaceutically acceptable carrier or it includes valeric acid and one or more neoplasm radiotheraphy secondary reaction protective agents.
7. pharmaceutical composition according to claim 6, it is characterised in that：The pharmaceutically acceptable carrier includes molten
Agent, cosolvent, emulsifier, corrigent, rectifys olfactory agent, colorant, adhesive, disintegrant, filler, lubricant, wetting at solubilizer
Agent, osmotic pressure regulator, pH adjusting agent, stabilizer, surfactant and/or preservative.
8. pharmaceutical composition according to claim 6, it is characterised in that：The neoplasm radiotheraphy secondary reaction protective agents include
Amifostine, Tiopronin, Aprepitant, Tropisetron, Ondansetron, Granisetron and/or palonosetron.
9. a kind of for preventing and/or treating the pharmaceutical preparation of neoplasm radiotheraphy secondary reaction, it includes therapeutically effective amount valeric acid and
One or more pharmaceutically acceptable carriers.
10. pharmaceutical preparation according to claim 9, it is characterised in that：The pharmaceutical preparation is solid pharmaceutical preparation, semisolid system
Agent or liquid preparation.
11. pharmaceutical preparation according to claim 10, it is characterised in that：The solid pharmaceutical preparation include tablet, capsule,
Granula and/or pill；The semisolid preparation includes gelling agent, suppository and/or paste；The liquid preparation includes emulsion, closes
Agent, suspension and/or solution.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711456216.9A CN108125940B (en) | 2017-12-28 | 2017-12-28 | Application of valeric acid in preparation of medicine for preventing and/or treating side effect of tumor radiotherapy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711456216.9A CN108125940B (en) | 2017-12-28 | 2017-12-28 | Application of valeric acid in preparation of medicine for preventing and/or treating side effect of tumor radiotherapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108125940A true CN108125940A (en) | 2018-06-08 |
| CN108125940B CN108125940B (en) | 2020-09-25 |
Family
ID=62393209
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711456216.9A Active CN108125940B (en) | 2017-12-28 | 2017-12-28 | Application of valeric acid in preparation of medicine for preventing and/or treating side effect of tumor radiotherapy |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108125940B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109758444A (en) * | 2019-03-27 | 2019-05-17 | 中国农业科学院特产研究所 | Application of the 2- methyl substituted fatty acid at anti-oxidant aspect |
| CN114259483A (en) * | 2020-09-16 | 2022-04-01 | 广州中医药大学第一附属医院 | Pharmaceutical composition for treating hepatocellular carcinoma and application thereof |
-
2017
- 2017-12-28 CN CN201711456216.9A patent/CN108125940B/en active Active
Non-Patent Citations (3)
| Title |
|---|
| MINGMING SUN，等: "Microbiota metabolite short chain fatty acids, GPCR, and inflammatory bowel diseases", 《JOURNAL OF GASTROENTEROLOGY》 * |
| 秦庆福，等: "放化疗对胃肠道的损伤以及微生态制剂防治的研究进展", 《中国微生态学杂志》 * |
| 胡琪璐，等: "放疗中氨磷汀应用副反应的临床观察", 《首都医药》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109758444A (en) * | 2019-03-27 | 2019-05-17 | 中国农业科学院特产研究所 | Application of the 2- methyl substituted fatty acid at anti-oxidant aspect |
| CN114259483A (en) * | 2020-09-16 | 2022-04-01 | 广州中医药大学第一附属医院 | Pharmaceutical composition for treating hepatocellular carcinoma and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108125940B (en) | 2020-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US3260646A (en) | Medication with mechanism to prevent overdosage | |
| CN108125950A (en) | Indolepopionic acid is being prepared for preventing and/or treat the purposes in the drug of neoplasm radiotheraphy secondary reaction | |
| CN101292969B (en) | Application of butyric acid (butanoic acid) in preparing medicaments for treating anorectal diseases | |
| KR101900520B1 (en) | A combination composition | |
| CN104382900A (en) | Compositions and methods for the treatment of radiation proctosigmoitis | |
| CN108125940A (en) | Valeric acid is being prepared for preventing and/or treat the purposes in the drug of neoplasm radiotheraphy secondary reaction | |
| CN101534840A (en) | Methods for the treatment of radiation proctosigmoitis | |
| Whittaker et al. | Recurrent laryngeal nerve paralysis in patients receiving vincristine and vinblastine. | |
| CN107106587A (en) | The purposes of albiflorin or the prevention of its pharmaceutically acceptable salt and/or treatment IBS | |
| CN100360120C (en) | Application of fenugreek total alkali extract in preparing medicine for ulcerative colitis and preparation method of colon targeted preparation | |
| Packard et al. | Management of severe tetanus | |
| WO2014050912A1 (en) | Liquid medicine having carbon dioxide dissolved therein, and therapeutic method using same | |
| Odunayo Akodu et al. | Dostarlimab: A Review of Its Pharmacology and Clinical Use in Management of Cancer | |
| CN114081880B (en) | Use of costunolide and its derivatives in preparation of medicine for preventing and/or treating intestinal injury | |
| CN104983829B (en) | A kind of Traditional Chinese medicine compound composition for treating ulcerative colitis and preparation method thereof and preparation | |
| CN104784651B (en) | A kind of method for preparing the pharmaceutical preparation for treating gastric ulcer | |
| RU2294204C1 (en) | Method for treatment of stomach and duodenum ulcerous disease | |
| Venter et al. | Sickle Cell Pain Crisis Complicated by Opioid Induced Hyperalgesia, Treated with Low Dose Ketamine Infusion | |
| Kennedy et al. | Malignant thyroid lymphoma presenting as acute airway obstruction | |
| Jentschura | Thyroid Disease and Taurine Consumption: A Case Study on Enzyme-Supported Immunotherapy | |
| US20060099172A1 (en) | Method of cancer screening; method of cancer treatment; method of diabetes treatment; method of multiple sclerosis treatment; method of prophylaxis and treatment of avian influenza | |
| RU2131733C1 (en) | Method of attenuation and prophylaxis of abstinent syndrome and agent for its realizing | |
| CN105748467B (en) | Pharmaceutical composition with effect of resisting lung cancer | |
| CN113197993A (en) | Traditional Chinese medicine composition for treating scrofula | |
| Tennant Jr | (−)-α-Acetylmethadol for treatment of chronic pain patients who abuse opioids |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20230707 Address after: 300192, 238 Bai Causeway Road, Tianjin, Nankai District Patentee after: INST OF RADIATION MEDICINE CHINESE ACAD OF MEDICAL SCIENCES Address before: Institute of Radiology, Chinese Academy of Medical Sciences, 238 Baidi Road, Nankai District, Tianjin, 300192 Patentee before: Cui Ming Patentee before: Fan Saijun Patentee before: Li Yuan Patentee before: Xiao Huiwen Patentee before: Zhang Shuqin |